

ChinaAMC Hang Seng Biotech ETF (Unlisted Class)

Fund Factsheet | As of 31 Oct 2025 New Capital Investment Entrant Scheme (New CIES) Eligible fund



Investment involves risks, including the loss of principal. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Biotech ETF (the "Fund"), investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

- The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Biotech Index (the "Index").
- The Fund is passively managed. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
- The Fund's investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
- The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
- The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and mainland China). The Fund may be more volatile than a broadly-based fund.
- The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
- The Fund is subject to securities lending transactions risks, including the risk that the borrower may fail to return the securities in a timely manner.
- The Fund is subject to tracking error risk.
- If any suspension of the inter-counter transfer of Listed Units and/or any limitation on the level of services by brokers and CCASS participants occurs, unitholders will only be able to trade their units in the relevant counter. The market price of Listed Units traded in each counter may deviate significantly.
- Unitholders will receive distributions in the HKD only. Unitholder without HKD account may have to bear the fees and charges associated with currency conversion.
- The Fund has units traded in HKD, RMB and USD. Secondary market investors may be subject to additional costs or losses associated with foreign currency fluctuations between HKD and RMB/USD.
- Listed and Unlisted Classes are subject to different pricing and dealing arrangements. NAV per Unit of each class may be different due to different fees and cost. Dealing deadlines in respect of Listed and Unlisted Classes are different. Trading hours of SEHK applicable to Listed Class in the secondary market and dealing deadlines in respect of the Listed Class on the primary market or Unlisted Class are also different.
- Units of Listed Class are traded in the secondary market on an intraday basis at the prevailing market price, while Units of Unlisted Class are sold through intermediaries based on the dealing day-end NAV. Investors of Unlisted Class could redeem at NAV while investors of Listed Class in the secondary market could only sell at the prevailing market price and may have to exit the Fund at a significant discount. Investors of Unlisted Class may be at an advantage or disadvantage compared to investors of Listed Class.
- The trading price of Listed Units is driven by market factors such as the demand and supply of the units. Therefore, Listed Units may trade at a substantial premium or discount to the Fund's NAV.
- The Fund may at its discretion pay dividend out of capital or effectively out of capital. Payment of dividends out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the NAV per Unit of the Fund.

Investment Objective

The investment objective of the Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Biotech Index.

Fund Information¹

Investment Manager	China Asset Management (Hong Kong) Limited
Trustee	HSBC Institutional Trust Services (Asia) Limited
Custodian	The Hongkong and Shanghai Banking Corporation Limited
Base Currency	HKD
Fund Size	HKD 1,449.26 million
Non-Base Currency Share Classes	RMB
Dealing Frequency	Daily


Available Share Classes

Share Class	Launch Date	NAV per share	Bloomberg Code	ISIN Code
Class B HKD	2024-11-18	HKD 15.3270	CAMBIHKB HK	HK0001043816
Class A RMB	2025-05-28	RMB 13.4157	CAMBIICNA HK	HK0001041117
Class A USD	2025-05-28	USD 1.3565	CAMBIUSA HK	HK0001041125

Source: Data as of 31 Oct 2025, Bloomberg, unless specified otherwise.

Share Class	Subscription Fee	Investment Management Fee	Min Initial Subscription
Class B HKD	Up to 3%	0.90%(p.a.)	HKD 1
Class A RMB	Up to 3%	0.40%(p.a.)	RMB 1000
Class A USD	Up to 3%	0.40%(p.a.)	USD 100

Fund Performance^{2,4}



Cumulative Performance (%)²

	1 Month	3 Month	6 Month	1 Year	Since Inception ⁴	Annualized Since Inception
Class B HKD	-10.96	-5.07	39.73	-	53.27	-

Yearly Performance (%)²

	2020	2021	2022	2023	2024	2025 YTD
Class B HKD	-	-	-	-	-	53.51

¹ Please refer to the Fund's prospectus for further details (including fees).

² Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is calculated on NAV-to-NAV. Performance analytics here refer to HKD counter unit.

³ Based on total return, denominated in HKD.

⁴ Calculated since 28 May 2025, the first official NAV date of the fund.

Source: China Asset Management (Hong Kong) Limited and Bloomberg unless specified otherwise.

ChinaAMC Hang Seng Biotech ETF (Unlisted Class)


Fund Factsheet | As of 31 Oct 2025

New Capital Investment Entrant Scheme (New CIES) Eligible fund



▲ Portfolio Allocation

Sector Exposure (%)



Customer Hotline: (852) 3406 8686

Website: www.chinaamc.com.hk

Email: hkfund_services@chinaamc.com

Important Note

Investment involves risks. The price of the Fund's units may go up as well as down. Past performance is not indicative of future performance, future return is not guaranteed and a loss of your original capital may occur. This material does not constitute an offer or solicitation of any transaction in any securities or collective investment schemes, nor does it constitute any investment advice. This document is provided for information purposes only and shall not be relied upon for making any investment decision. Certain information or data in this document has been obtained from unaffiliated third parties; we have reasonable belief that such information or data is accurate, complete and up to the date as indicated; China Asset Management (Hong Kong) Limited accepts responsibility for accurately reproducing such data and information but makes no warranty or representation as to the completeness and accuracy of data and information sourced from such unaffiliated third parties. You should read the Fund's offering documents for further details, including risk factors. If necessary, you should seek independent professional advice. This material has been prepared and issued by China Asset Management (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission.

Index Disclaimer

The Hang Seng Biotech Index is published and compiled by HSIL pursuant to a licence from Hang Seng Data Services Limited ("HSDS"). The mark and name "Hang Seng Biotech Index" is proprietary to HSDS. HSIL and HSDS have agreed to the use of, and reference to, the Hang Seng Biotech Index by the Manager and the Trustee and their respective duly appointed agents in connection with ChinaAMC Hang Seng Biotech ETF, but neither HSIL nor HSDS warrants or represents or guarantees to any broker or holder of the ChinaAMC Hang Seng Biotech ETF or any other person (i) The accuracy or completeness of the Hang Seng Biotech Index and its computation or any information related thereto; or (ii) The fitness or suitability for any purpose of the Hang Seng Biotech Index or any component or data comprised in it; or (iii) The results which may be obtained by any person from the use of the Hang Seng Biotech Index or any component or data comprised in it for any purpose, and no warranty or representation or guarantee of any kind whatsoever relating to the Hang Seng Biotech Index is given or may be implied. The process and basis of computation and compilation of the Hang Seng Biotech Index and any of the related formula or formulae, constituent stocks and factors may at any time be changed or altered by HSIL without notice. To the extent permitted by applicable law, no responsibility or liability is accepted by HSIL or HSDS (i) In respect of the use of and/or reference to the Hang Seng Biotech Index by the manager in connection with ChinaAMC Hang Seng Biotech ETF; or (ii) For any inaccuracies, omissions, mistakes or errors of HSIL in the computation of the Hang Seng Biotech Index; or (iii) for any inaccuracies, omissions, mistakes, errors or incompleteness of any information used in connection with the computation of the Hang Seng Biotech Index which is supplied by any other person; or (iv) For any economic or other loss which may be directly or indirectly sustained by any broker or holder of the ChinaAMC Hang Seng Biotech ETF or any other person dealing with ChinaAMC Hang Seng Biotech ETF as a result of any of the aforesaid, and no claims, actions or legal proceedings may be brought against HSIL and/or HSDS in connection with ChinaAMC Hang Seng Biotech ETF in any manner whatsoever by any broker, holder or any other person dealing with ChinaAMC Hang Seng Biotech ETF. Any broker, holder or other person dealing with ChinaAMC Hang Seng Biotech ETF does so therefore in full knowledge of this disclaimer and can place no reliance whatsoever on HSIL and HSDS. For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker, holder or other person and HSIL and/or HSDS and must not be construed to have created such relationship.